FDA accepts for NDA investigational hypertension drug
from Pharmacy Times
The FDA has accepted the new drug application for EZR-201, an investigational product from Ezra Innovations for the treatment of hypertension and heart failure. EZR-201 combines an angiotensin receptor blocker, valsartan, with Rubireten delivery technology.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063